Annotated Bibliography

This annotated bibliography documents every peer-reviewed article used to develop content in the Research Hub. Each entry includes the full APA 7 citation, a summary annotation describing the study's purpose, methodology, and key findings, and links to the original source. Papers that appear in multiple resources are listed once.

Adesida, S. O., Oyetunji, R. A., & Alimba, C. G. (2026). Bioactive compounds from edible mushrooms as pharmaceutical ingredients: A comprehensive review of the developmental pipeline. Processes, 14(5), 795. https://doi.org/10.3390/pr14050795

This comprehensive narrative review examines the developmental pipeline for translating edible mushroom-derived bioactive compounds—including β-glucans, lectins, ganoderic acids, cordycepin, and phenolic compounds—into standardized pharmaceutical ingredients. The authors identify a significant translational gap between promising preclinical evidence and clinical drug development, attributing it to challenges in standardization, bioavailability, and regulatory classification. By systematically cataloguing the mechanisms behind immunomodulatory, anticancer, antioxidant, and anti-inflammatory activities, the review provides a practical roadmap for advancing mushroom science toward pharmaceutical applications.

Aditya, Neeraj, & Bhatia, J. N. (2024). Medicinal mushrooms and their impact on human health. Food and Scientific Reports, 5(1), 38–43.

This open-access review catalogues the primary medicinal mushroom species—including Reishi, Shiitake, Lion's Mane, Cordyceps, Turkey Tail, Chaga, and Maitake—and summarizes their documented health benefits across immune function, inflammation, cardiovascular health, blood sugar regulation, and cancer prevention. The authors provide a species-by-species breakdown of bioactive compounds (β-glucans, triterpenoids, and polysaccharides) and their proposed mechanisms of action. Published in a peer-reviewed Indian agricultural science journal, the piece serves as an accessible overview of the functional mushroom landscape.

Alataa, R., Farag, M., Hallal, P. L., & Harish, P. (2025). Unrecognized antiplatelet effect of mushroom coffee: A case of postoperative bleeding following colonic surgery. Gastrointestinal Disorders, 8(1), 3.

This case report documents an unanticipated perioperative complication in a 62-year-old patient who had consumed mushroom coffee containing cordyceps, lion's mane, reishi, shiitake, turkey tail, and king trumpet for two months prior to colonic surgery, subsequently developing severe postoperative anastomotic bleeding requiring angiographic embolization. A plausible mechanism is established through the known antiplatelet and anticoagulant properties of functional mushroom compounds, highlighting a critical gap in perioperative medication assessment protocols. The case underscores the clinical importance of including functional mushroom supplement use in standard pre-surgical medication reviews.

Araújo, P. L., Araújo, E. d. S., Barreto, E. M. d. A., Alves, J. L. d. B., Souza, K. M., Freire, M. O. d. L., Souza, R. M. P. d., & Pereira, F. d. O. (2025). Pleurotus mushrooms in nutrition and health: Clinical and preclinical insights for nutraceutical development. Comprehensive Reviews in Food Science and Food Safety, 24(5), e70279.

Ashraf, S. A., Elkhalifa, A. E. O., Siddiqui, A. J., Patel, M., Awadelkareem, A. M., Snoussi, M., Ashraf, M. S., Adnan, M., & Hadi, S. (2020). Cordycepin for health and wellbeing: A potent bioactive metabolite of an entomopathogenic medicinal fungus Cordyceps with its nutraceutical and therapeutic potential. Molecules, 25(12), 2735.

This comprehensive review synthesizes the accumulated pharmacological evidence for cordycepin (3′-deoxyadenosine)—the flagship bioactive compound of Cordyceps militaris—across therapeutic domains including antitumor, antiviral, anti-inflammatory, immunomodulatory, antidiabetic, and neuroprotective activities. The authors detail cordycepin's mechanism of action as a modified adenosine analog that inhibits mRNA polyadenylation and activates AMPK signaling, disrupting both cancer cell metabolism and inflammatory cascades. The review provides the most comprehensive single-source pharmacological treatment of cordycepin available in the literature and serves as an essential reference for researchers investigating Cordyceps-derived nutraceuticals.

Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2017). Neuroticism is associated with challenging experiences with psilocybin mushrooms. Personality and Individual Differences, 117, 155–160.

This study investigated personality traits as predictors of challenging (difficult or frightening) experiences during psilocybin sessions in healthy volunteers, finding that higher scores on the neuroticism dimension of the Big Five personality model were significantly associated with adverse acute reactions. The findings suggest that pre-session psychological screening—particularly for neuroticism—could help clinicians identify individuals who may require additional therapeutic preparation or support. This work has directly informed patient selection and preparation protocols in psilocybin-assisted therapy research programs.

Bell, V., Dimitrov, P., & Fernandes, T. (2025). Supporting neurologic health with mushroom nutrition. Nutrients, 17(9), 1568. https://doi.org/10.3390/nu17091568

This review synthesizes evidence for mushroom-derived compounds as supports for neurological health, with particular emphasis on Hericium erinaceus (Lion's Mane) and its unique erinacine and hericenone compounds, which stimulate nerve growth factor (NGF) synthesis and may support cognitive function, peripheral nerve regeneration, and protection against neurodegenerative conditions. The authors also review evidence for neuroprotective polysaccharides from Ganoderma lucidum and other species, and discuss emerging human clinical trial data. The paper positions mushroom nutrition as a meaningful complement to conventional neurological care.

Bogenschutz, M. P., Podrebarac, S. K., Duane, J. H., Amegadzie, S. S., Malone, T. C., Owens, L. T., Ross, S., & Mennenga, S. E. (2018). Clinical interpretations of patient experience in a trial of psilocybin-assisted psychotherapy for alcohol use disorder. Frontiers in Pharmacology, 9, Article 100.

This paper looks at what patients went through during a trial of psilocybin therapy for alcohol use disorder. The researchers studied session recordings and patient reports. They wanted to learn how the experience might help people change their drinking. Common themes came up: new insight, strong emotions, and a sense of meaning. The authors say these personal experiences, not just the drug, play a key role in recovery. It is free to read in Frontiers in Pharmacology.

Bogenschutz, M. P., Ross, S., Bhatt, S., Baron, T., Forcehimes, A. A., Laska, E., Mennenga, S. E., O'Donnell, K., Owens, L. T., Podrebarac, S., Rotrosen, J., Tonigan, J. S., & Worth, L. (2022). Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: A randomized clinical trial. JAMA Psychiatry, 79(10), 953–962.

This was a carefully designed clinical trial of psilocybin therapy for alcohol use disorder. Nearly 100 adults got either psilocybin or a placebo, plus talk therapy. Neither they nor the staff knew which they got. The psilocybin group cut their heavy drinking days far more than the placebo group. This is some of the strongest evidence yet that psilocybin can help people drink less. It is free to read in JAMA Psychiatry.

Bradshaw, A. J., Backman, T. A., Ramírez-Cruz, V., Forrister, D. L., Winter, J. M., Guzmán-Dávalos, L., Furci, G., Stamets, P., & Dentinger, B. T. M. (2022). DNA authentication and chemical analysis of Psilocybe mushrooms reveal widespread misdeterminations in fungaria and inconsistencies in metabolites. Applied and Environmental Microbiology, 88(24), e01498-22.

This methodologically rigorous study applied DNA barcoding combined with metabolite analysis to specimens from international fungaria (museum mushroom collections), revealing that a substantial proportion of samples labeled as specific Psilocybe species were incorrectly identified, and that psilocybin, psilocin, baeocystin, and norbaeocystin content varied enormously even within correctly identified specimens. The findings have significant implications for both taxonomic research and the quality control of materials used in clinical psilocybin research. For microscopy researchers, the paper provides an authoritative reference on species authentication methods and highlights the limitations of morphology-only identification.

Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S., MacLean, K. A., Jesse, R., Johnson, M. W., & Griffiths, R. R. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of Psychopharmacology, 30(12), 1268–1278.

This survey study recruited participants who had ingested psilocybin mushrooms and reported challenging or difficult experiences, collecting data on both the acute negative aspects of those sessions and their enduring effects—positive, negative, or neutral—in the weeks and months following. Despite the difficulty of the acute experience, the majority of respondents attributed lasting positive meaning to their challenging sessions, with a significant minority rating the experience as among the most personally meaningful of their lives. The study provides foundational empirical evidence for the therapeutic paradox at the heart of psilocybin research: that difficult, frightening, or overwhelming experiences frequently produce the most significant and lasting positive transformations.

Carhart-Harris, R. L., Roseman, L., Bolstridge, M., Demetriou, L., Pannekoek, J. N., Wall, M. B., Tanner, M., Kaelen, M., McGonigle, J., Murphy, K., Leech, R., Curran, H. V., & Nutt, D. J. (2017). Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Scientific Reports, 7, 13187.

This neuroimaging study used functional MRI to measure brain activity changes in 20 patients with treatment-resistant depression before and after psilocybin-assisted therapy, finding increased amygdala responsiveness to emotional stimuli post-treatment and significant reductions in default mode network (DMN) activity during acute drug effects. The hyperactive DMN characteristic of depression appeared to be disrupted by psilocybin in a way that correlated with antidepressant outcomes, providing mechanistic support for the therapeutic hypothesis. This paper remains a foundational reference for understanding the neurological basis of psilocybin's antidepressant effects.

Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine, 384(15), 1402–1411.

This landmark double-blind randomized controlled trial compared two sessions of psilocybin-assisted therapy against a six-week course of the SSRI escitalopram in 59 patients with moderate-to-severe major depressive disorder. While the primary outcome did not reach statistical significance in favor of psilocybin, psilocybin showed superiority on multiple secondary measures including emotional well-being, anhedonia, and psychological connectedness. Published in the New England Journal of Medicine, this trial significantly elevated the scientific credibility of psilocybin as a candidate antidepressant treatment.

Chen, S., Li, Z., Krochmal, R., Abrazado, M., Kim, W., & Cooper, C. B. (2010). Effect of Cs-4® (Cordyceps sinensis) on exercise performance in healthy older subjects: A double-blind, placebo-controlled trial. Journal of Alternative and Complementary Medicine, 16(5), 585–590.

This randomized, double-blind, placebo-controlled trial administered Cs-4® (a standardized Cordyceps sinensis preparation) to 20 healthy older adults for 12 weeks, measuring VO₂ max, ventilatory threshold, and exercise tolerance before and after supplementation. The Cs-4 group showed significant improvements in maximal oxygen uptake and exercise tolerance compared to placebo, with the strongest effects observed in participants over 50 years old. Published in the Journal of Alternative and Complementary Medicine, this study provides the strongest placebo-controlled human evidence for Cordyceps as an ergogenic aid and is widely cited as the clinical anchor for athletic performance claims.

Chen, L., Liu, X., Zheng, K., Wang, Y., Li, M., Zhang, Y., Cui, Y., Deng, S., Liu, S., Zhang, G., Li, L., & He, Y. (2024). Cordyceps polysaccharides: A review of their immunomodulatory effects. Molecules, 29(21), Article 5107.

Cordyceps mushrooms contain natural sugars called polysaccharides. This review gathers 20 years of studies, from 2004 to 2024, on how those sugars affect the immune system. Most of the research looked at two species, Cordyceps sinensis and Cordyceps militaris. The studies show these sugars can switch on key immune cells, such as macrophages and lymphocytes. They also help the body make more of its own immune signals. In animal tests, the sugars rebuilt immune strength lost to drugs or radiation. They also helped the body fight tumors. The review is free to read in the journal Molecules.

Chihara, G., Hamuro, J., Maeda, Y. Y., Shiio, T., Suga, T., Takasuka, N., & Sasaki, T. (1987). Antitumor and metastasis-inhibitory activities of lentinan as an immunomodulator: An overview. Cancer Detection and Prevention Supplement, 1, 423–443.

This foundational review from one of lentinan's original discoverers and most prominent clinical researchers summarizes the preclinical and early clinical evidence for lentinan as an antitumor and anti-metastatic biological response modifier, establishing the conceptual framework that would guide decades of subsequent clinical investigation. Chihara and colleagues describe lentinan's mechanism as T-cell-dependent potentiation of host immune response rather than direct cytotoxicity, a distinction that positioned it as the prototype biological response modifier in cancer immunotherapy research. Published in Cancer Detection and Prevention Supplement in 1987, this paper is the historical anchor for all subsequent lentinan research and is the primary reference for its foundational pharmacology.

Chong, P. S., Fung, M.-L., Wong, K. H., & Lim, L. W. (2020). Therapeutic potential of Hericium erinaceus for depressive disorder. International Journal of Molecular Sciences, 21(1), Article 163.

This review asks whether Lion's Mane mushroom can help with depression. Compounds in the mushroom push the body to make nerve growth factor, or NGF. NGF is a protein that helps brain cells grow and stay healthy. That is a different path than most antidepressants, which mainly change brain chemicals like serotonin. The authors are careful to make one point. Lion's Mane has not been tested head-to-head against standard antidepressants in people. So it is not a proven treatment. Still, its effect on brain-cell growth makes it worth more study. The review is free to read in the International Journal of Molecular Sciences.

Chopra, H., Furnish, T., Verduzco-Gutierrez, M., Jevotovsky, D. S., & Castellanos, J. (2024). Long-COVID symptoms improved after MDMA and psilocybin therapy: A case report. Clinical Case Reports, 12, e8791.

This case report describes a patient with post-COVID-19 syndrome experiencing persistent fatigue, brain fog, and post-exertional malaise who reported substantial symptom improvement following psilocybin and MDMA therapy administered in a clinical setting. The authors propose several mechanisms including anti-inflammatory effects, neuroplasticity-driven cognitive restoration, and modulation of serotonin signaling as potential explanatory pathways. While a single case report cannot establish causality, this publication is among the first to formally document psychedelic-assisted therapy in the context of Long-COVID and opens an important area of inquiry.

Cohen, J., Sulimani, L., Procaccia, S., Lerenthal, Y., Milay, L., Taran, I., Shapira, A., & Meiri, D. (2025). Comprehensive analysis of 42 psilocybin-producing fungal strains reveals metabolite diversity and species-specific clusters. Scientific Reports, 15(1), Article 13822.

This analytical chemistry and chemotaxonomy study profiled the secondary metabolite content of 42 psilocybin-producing fungal strains from six Psilocybe species using high-performance liquid chromatography coupled with mass spectrometry, revealing substantial variation in psilocybin, psilocin, baeocystin, and norbaeocystin concentrations both within and between species. Cluster analysis identified species-specific metabolite fingerprints that could serve as chemotaxonomic markers, while within-species variation highlighted the importance of strain-level characterization for pharmaceutical and research applications. Published in Scientific Reports with open access, this study provides the most comprehensive multi-strain metabolite dataset available in the peer-reviewed literature and has direct implications for standardization efforts in clinical psilocybin research.

COMPASS Pathways, Ltd. (2019). Clinical Protocol COMP 001: The Safety and Efficacy of Psilocybin in Participants with Treatment-Resistant Depression (P-TRD) [Clinical trial protocol]. ClinicalTrials.gov Identifier: NCT03775200.

This is the foundational clinical trial protocol for COMP 001, COMPASS Pathways' Phase 2 randomized controlled trial of psilocybin (COMP360) in adults with treatment-resistant depression, registered as ClinicalTrials.gov NCT03775200 with a study start date of March 2019. The protocol established the dosing strategy (single 25 mg, 10 mg, or 1 mg session of synthesized psilocybin alongside psychological support), patient eligibility criteria (treatment-resistant depression failing at least two prior antidepressant trials), screening procedures, primary and secondary outcome measures (Montgomery–Åsberg Depression Rating Scale change at three weeks), and the safety monitoring framework. The framework defined here became the reference point for subsequent industry-sponsored psilocybin depression trials and shaped the regulatory pathway that produced FDA Breakthrough Therapy designation for psilocybin in treatment-resistant depression.

Couto, J. S., & Silva, D. P. (2008). Coriolus versicolor supplementation in HPV patients. Proceedings of the 20th European Congress of Obstetrics and Gynaecology.

This conference presentation reported clinical outcomes in a series of HPV-positive patients who received Coriolus versicolor supplementation, documenting a high rate of HPV clearance and regression of cervical lesions compared to untreated controls. While published only as conference proceedings and limited by its non-randomized design, the findings gained significant attention because they aligned with the known immunostimulatory mechanisms of PSK and PSP and suggested a potential role for Turkey Tail in gynecological viral oncology. The report has subsequently been cited in multiple reviews as preliminary but clinically significant evidence warranting controlled trial investigation.

Crowe, M., Manuel, J., Carlyle, D., & Lacey, C. (2023). Experiences of psilocybin treatment for clinical conditions: A qualitative meta-synthesis. International Journal of Mental Health Nursing, 32(4), 1025–1037.

This qualitative meta-synthesis systematically integrated findings from multiple qualitative studies examining what patients experience during and after psilocybin treatment for clinical conditions including depression, addiction, and existential distress in terminal illness. Key themes identified included the transformative impact of mystical or peak experiences, the importance of therapeutic relationship and set and setting, the challenges of integration, and a general sense of reconnection to self, others, and meaning. The synthesis provides the most comprehensive patient-centered account of psilocybin therapy available in the published literature.

Daoust, J., Schmalz, J., Van Meulebroek, L., Ghyselinck, J., Verstrepen, L., & Marzorati, M. (2025). Prebiotic activity of functional whole mushroom powders in short-term in vitro colonic simulations. Journal of Functional Foods, 126, 106912. https://doi.org/10.1016/j.jff.2025.106912

Using a validated short-term in vitro colonic fermentation model, this study assessed the prebiotic potential of whole mushroom powders including lion's mane, reishi, and cordyceps, comparing them to inulin as a positive control. All tested mushroom powders stimulated the production of short-chain fatty acids—particularly butyrate—and selectively increased populations of health-associated bacteria including Bifidobacterium and Lactobacillus, with mycelium-containing powders showing the strongest activity. The findings provide mechanistic evidence supporting functional mushrooms' role in gut microbiome modulation and digestive health.

Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry, 78(5), 481–489.

This randomized clinical trial enrolled 24 adults with major depressive disorder who had no prior psychedelic therapy experience, finding that two sessions of psilocybin-assisted therapy produced rapid, substantial, and durable antidepressant effects, with 71% of participants classified as treatment responders and 54% in full remission at the four-week follow-up. While the open-label design and small sample size are noted limitations, the large effect sizes and durability of response are clinically striking. Published in JAMA Psychiatry, this study contributed significantly to the evidence base supporting psilocybin for non-treatment-resistant depression.

Daws, R. E., Timmermann, C., Giribaldi, B., Sexton, J. D., Wall, M. B., Erritzoe, D., Roseman, L., Nutt, D., & Carhart-Harris, R. (2022). Increased global integration in the brain after psilocybin therapy for depression. Nature Medicine, 28(4), 844–851.

This brain-imaging study looked at how psilocybin therapy changes the brain in people with depression. Using fMRI scans, the researchers found that after treatment, brain networks became more flexible and better connected. This change was linked to patients feeling less depressed. The pattern was not seen with a standard antidepressant, which suggests psilocybin may work in a different way. The abstract is free to read; the full article needs journal access.

de la Salle, S., Kettner, H., Thibault Lévesque, J., Garel, N., Dames, S., Patchett-Marble, R., Rej, S., Gloeckler, S., Erritzoe, D., Carhart-Harris, R., & Greenway, K. T. (2024). Longitudinal experiences of Canadians receiving compassionate access to psilocybin-assisted psychotherapy. Scientific Reports, 14, 15353.

This prospective observational study followed 26 Canadian patients who received psilocybin-assisted psychotherapy through Health Canada's Special Access Program (SAP), collecting longitudinal self-report data at multiple timepoints before and after treatment across a range of clinical conditions including depression, PTSD, end-of-life distress, and substance use disorders. Participants reported significant and sustained improvements in mental health outcomes and quality of life, with the therapeutic relationship and integration support identified as key factors in outcomes. As the first peer-reviewed study of real-world compassionate access outcomes in Canada, this paper provides critical evidence for policymakers, clinicians, and patients navigating psilocybin access outside of formal clinical trials.

Di Renzo, T., Reale, A., Nazzaro, S., Marena, P., Rahim, M. H. A., Mohd Zaini, N. A., Daud, N. A., & Wan-Mohtar, W. A. A. Q. I. (2025). Performance of mushrooms in fermented beverages: A narrative review. Beverages, 11(1), 19. https://doi.org/10.3390/beverages11010019

This narrative review examines the growing incorporation of mushrooms into fermented beverages including kombucha, kefir, beer, and wine, evaluating how fermentation processes interact with mushroom-derived β-glucans, polysaccharides, phenolic compounds, and bioactive proteins. The authors find that fermentation generally enhances the bioaccessibility and bioavailability of mushroom bioactive compounds, while also modifying flavor profiles in ways that may increase consumer acceptance. The review identifies functional mushroom-fermented beverages as a promising frontier in nutraceutical food product development.

Docherty, S., Doughty, F. L., & Smith, E. F. (2023). The acute and chronic effects of lion's mane mushroom supplementation on cognitive function, stress and mood in young adults: A double-blind, parallel groups, pilot study. Nutrients, 15(22), 4842.

This double-blind, parallel-groups pilot study measured both acute (60-minute post-dose) and chronic (28-day supplementation) effects of Lion's Mane mushroom on cognitive function, stress biomarkers, and mood in healthy young adults. Acute testing demonstrated improved speed on a cognitive battery immediately after supplementation, while the chronic arm showed reduced subjective stress scores after four weeks. The pilot design and small sample size necessitate replication, but the data contribute meaningfully to understanding the time-course dynamics of Lion's Mane's cognitive effects—distinguishing immediate nootropic-like actions from longer-term neuroadaptive benefits.

Domagalska, J., Rusin, M., Rogala, D., Gut-Pietrasz, K., & Buczkowska, M. (2026). Evaluation of toxic elements in commercial dried mushrooms from the Polish market: Exposure assessment and health risk characterization. Molecules, 31(11), 1865.

Enman, J., Rova, U., & Berglund, K. A. (2007). Quantification of the bioactive compound eritadenine in selected strains of shiitake mushroom (Lentinus edodes). Journal of Agricultural and Food Chemistry, 55(4), 1177–1180.

This study quantified eritadenine—a sulfur-containing adenosine analog unique to Shiitake mushrooms that inhibits S-adenosylhomocysteine hydrolase and thereby reduces hepatic cholesterol synthesis—across multiple commercial and experimental Lentinus edodes strains, finding significant variation in eritadenine content between strains and a strong correlation between eritadenine concentration and the degree of LDL cholesterol reduction observed in feeding experiments. The findings demonstrate that not all shiitake strains are equivalent for cardiovascular health applications and establish strain-specific eritadenine quantification as an important quality control parameter for functional shiitake products. Published in the Journal of Agricultural and Food Chemistry, this paper is the definitive analytical chemistry reference for eritadenine in shiitake.

Fernandes, T., Garrine, C., Ferrão, J., Bell, V., & Varzakas, T. (2021). Mushroom nutrition as preventative healthcare in sub-Saharan Africa. Applied Sciences, 11(9), 4221. https://doi.org/10.3390/app11094221

This review examines the role of edible and medicinal mushrooms as preventative healthcare resources in the Sub-Saharan African context, where protein-energy malnutrition, infectious disease burden, and limited access to pharmaceutical healthcare create significant public health challenges. The authors highlight mushrooms' exceptional nutritional density (protein, vitamins B and D, minerals, and dietary fiber), immune-modulating β-glucans, and low cost of cultivation as attributes that align well with the region's healthcare needs. The paper makes a compelling case for investment in mushroom cultivation programs as a scalable public health intervention.

Fijałkowska, A., Jędrejko, K., Sułkowska-Ziaja, K., Ziaja, M., Kała, K., & Muszyńska, B. (2022). Edible mushrooms as a potential component of dietary interventions for major depressive disorder. Foods, 11(10), 1489.

This review synthesizes evidence for the potential role of edible mushrooms as a dietary component in managing major depressive disorder (MDD), noting that mushrooms are among the richest dietary sources of ergothioneine, contain serotonin precursors, and include species—particularly Hericium erinaceus—whose NGF-stimulating compounds have demonstrated antidepressant effects in preclinical and early clinical studies. The authors also review mushrooms' anti-inflammatory properties in the context of the inflammatory hypothesis of depression. The paper positions functional mushrooms as a potentially meaningful dietary intervention that warrants further clinical investigation for MDD.

Fleury, V., Tomkova, E., Catalano Chiuvé, S., & Penzenstadler, L. (2025). Psilocybin-assisted psychotherapy for Parkinson's disease without depression: A case report. Journal of Parkinson's Disease, 15(2), 440–444.

This is a single case report describing a person with Parkinson's disease who received psilocybin therapy. The patient was not depressed but struggled to accept and adjust to the illness. After psilocybin sessions, she became less anxious and more hopeful about her future. As a report of just one patient, it cannot prove the treatment works, but it suggests a question worth studying. It is free to read in the Journal of Parkinson's Disease.

Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 187(3), 268–292.

This foundational double-blind study administered high-dose psilocybin to 36 spiritually engaged adults with no prior hallucinogen experience in a controlled setting, finding that 67% of participants rated the session as among the five most personally meaningful experiences of their lives, and 61% as among the five most spiritually significant. Positive attitude change, mood, and behavior were reported at two-month follow-up, with ratings corroborated by family members and friends who were unaware of the study conditions. This study established the template for modern psilocybin research methodology and remains the most widely cited paper in the field.

Hughes, J., Stuart-Bennett, J., Dunning, M., & Farrimond, H. (2025). Towards a dynamic processual model of psychedelic microdosing. International Journal of Drug Policy, 136, 104691.

Drawing on in-depth qualitative interviews with people who microdose psilocybin, this study proposes a "dynamic processual model" that maps microdosing experiences as evolving over time through phases of initiation, active use, integration, and adaptation, rather than as a static or uniform practice. The model challenges reductive accounts of microdosing as simply producing consistent cognitive enhancement, finding that effects varied significantly by individual, context, dosing protocol, and time in the practice. The paper provides a nuanced framework for understanding the wide variability of self-reported microdosing outcomes.

Hyde, K. D., Bahkali, A. H., & Moslem, M. A. (2010). Fungi—an unusual source for cosmetics. Fungal Diversity, 43, 1–9. https://doi.org/10.1007/s13225-010-0043-3

This review catalogues fungal species currently used or patented for use in cosmeceutical and nutricosmetic products, covering Ganoderma lucidum, Lentinula edodes, Trametes versicolor, Tremella fuciformis, and Cordyceps sinensis, among others. The authors identify specific bioactive compounds of cosmetic relevance—including kojic acid (skin lightening), polysaccharides (moisturization), ergosterol (pro-vitamin D), and β-glucans (anti-aging)—and discuss their mechanisms of action in personal care applications. The review expands the lens on functional mushrooms beyond food and medicine to the rapidly growing cosmetics and personal care industry.

Ina, K., Kataoka, T., & Ando, T. (2013). The use of lentinan in treating gastric cancer. Anti-Cancer Agents in Medicinal Chemistry, 13(5), 681–688.

This review summarizes clinical experience with lentinan—the β-1,3/1,6-glucan immunomodulator derived from Shiitake mushrooms—as an adjuvant treatment for gastric cancer in Japan and China, covering its mechanism of action via Dectin-1 receptor activation and downstream MAPK-NF-κB signaling, as well as clinical evidence from randomized controlled trials demonstrating improved survival outcomes when lentinan is combined with chemotherapy. The authors note that lentinan is most effective as a biological response modifier rather than a direct cytotoxic agent, and highlight its established safety profile following decades of clinical use. Published in Anti-Cancer Agents in Medicinal Chemistry, this review is the primary reference for lentinan's clinical evidence base in gastric oncology.

James, E., Robertshaw, T. L., Hoskins, M., & Sessa, B. (2020). Psilocybin occasioned mystical-type experiences. Human Psychopharmacology: Clinical and Experimental, 35(5), e2742.

This study examined the phenomenology of mystical-type experiences occasioned by psilocybin, characterizing their common features—including unity, noetic quality, transcendence of time and space, sacredness, deeply felt positive mood, and ineffability—and their relationship to therapeutic outcomes and lasting well-being. The authors discuss how the intensity and completeness of the mystical experience, as measured by validated scales such as the MEQ-30, appears to mediate the magnitude of lasting positive personality and well-being changes. The paper reinforces the clinical significance of the subjective experience itself as a core mechanism of therapeutic action.

Jin, X., Ruiz Beguerie, J., Sze, D. M.-Y., & Chan, G. C.-F. (2012). Ganoderma lucidum (Reishi mushroom) for cancer treatment. Cochrane Database of Systematic Reviews, 6, CD007731.

This Cochrane systematic review assessed the totality of randomized and quasi-randomized controlled trial evidence for Ganoderma lucidum as a cancer treatment, ultimately identifying five eligible trials involving 373 participants with breast, lung, and prostate cancers. The reviewers found insufficient evidence to recommend Reishi as first-line cancer therapy but concluded that Reishi could be considered as a complementary treatment alongside conventional therapy, given evidence of improved immune function and quality of life with no serious safety concerns identified. As a Cochrane review—the highest tier of systematic evidence synthesis—this paper is the most authoritative summary of clinical trial evidence for Reishi in oncology.

Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT2A receptor agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology, 28(11), 983–992.

This small pilot study tested psilocybin as a tool to help people quit smoking. Fifteen long-term smokers took psilocybin as part of a structured quit-smoking program with counseling. Six months later, 12 of the 15 had stopped smoking, a much higher success rate than usual methods. The study was small and had no comparison group, but the strong results pointed to a promising new approach. It is free to read on PubMed Central.

Johnson, M. W., Naudé, G. P., Hendricks, P. S., & Garcia-Romeu, A. (2026). Psilocybin or nicotine patch for smoking cessation: A pilot randomized clinical trial. JAMA Network Open, 9(3), e260972.

Kirdeeva, Y., Fefilova, E., Karpova, N., Parfenyev, S., Daks, A., Nazarov, A., Semenov, O., Van Anh, N. T., Loc, V. T., Cuong, N. M., & Shuvalov, O. (2026). The inclusion of dietary and medicinal mushrooms into translational oncology: Pros and cons at the molecular level. International Journal of Molecular Sciences, 27(3), 1312. https://doi.org/10.3390/ijms27031312

This molecular-level review examines both the promising and problematic aspects of incorporating dietary and medicinal mushrooms into cancer treatment, surveying evidence for immunostimulatory β-glucans, antiproliferative ganoderic acids, and polysaccharide K (PSK from Turkey Tail) as oncological adjuvants, while also critically analyzing reported pro-tumor mechanisms and potential drug interactions. The authors find particularly strong evidence for PSK and polysaccharide peptide (PSP) as adjuncts to chemotherapy, where randomized controlled trials in Japan and China have shown improved survival outcomes. The paper provides a balanced, mechanistically grounded guide for clinicians and researchers considering mushroom compounds in oncological contexts.

Koh, J. H., Kim, K. M., Kim, J. M., Song, J. C., & Suh, H. J. (2003). Antifatigue and antistress effect of the hot-water fraction from mycelia of Cordyceps sinensis. Biological and Pharmaceutical Bulletin, 26(5), 691–694.

This study administered the hot-water-soluble fraction of Cordyceps sinensis mycelia to mice using a chronic forced swim stress model, measuring swim time to exhaustion, blood chemistry markers, and corticosterone levels as indices of fatigue and HPA axis stress response. Cordyceps-treated mice demonstrated significantly longer swim times and lower corticosterone levels than controls, suggesting both physical fatigue resistance and adaptogenic blunting of the stress response. The paper established the antifatigue and antistress mechanisms of Cordyceps in a validated rodent model and was one of the early pharmacological studies to support the traditional Chinese medicinal use of Cordyceps for stamina and energy.

Kurzbaum, E., Páleníček, T., Sharchaton, A., Azerrad, S., & Dekel, Y. (2025). Exploring Psilocybe cubensis strains: Cultivation techniques, psychoactive compounds, genetics and research gaps. Journal of Fungi, 11(2), Article 99.

This extensive review synthesizes knowledge across three domains of Psilocybe cubensis biology: cultivation methodologies (substrate composition, environmental parameters, and yield optimization), psychoactive compound profiles (psilocybin, psilocin, baeocystin, and norbaeocystin across strains), and current understanding of the genetics and genomics governing tryptamine biosynthesis. The authors identify significant research gaps in strain-level genetic characterization and dose standardization, and call for systematic comparative studies across named P. cubensis strains. Published in Journal of Fungi with open access, the review is particularly valuable for researchers seeking a single authoritative reference covering cultivation science, analytical chemistry, and molecular genetics of the most studied psilocybin-producing species.

Lago, M., Cerveira, M., & Simonet, J. X. (2026). Transient multidomain functional improvement in advanced Alzheimer's disease following high-dose psilocybin-containing mushroom administration: A case report. Frontiers in Neuroscience, 20, Article 1813281.

This case report describes a person with advanced Alzheimer's disease. They were given a high dose of psilocybin-containing mushrooms. For a short time afterward, the patient showed surprising gains in speech, movement, and awareness. The authors note this is a single case, and the effects did not last. So it cannot prove anything on its own. Still, they argue it raises questions worth careful study. It is free to read in Frontiers in Neuroscience.

Li, I.-C., Chang, H.-H., Lin, C.-H., Chen, W.-P., Lu, T.-H., Lee, L.-Y., Chen, Y.-W., Chen, Y.-P., Chen, C.-C., & Lin, D.-P. (2020). Prevention of early Alzheimer's disease by erinacine A-enriched Hericium erinaceus mycelia pilot double-blind placebo-controlled study. Frontiers in Aging Neuroscience, 12, 155.

This pilot double-blind, placebo-controlled study investigated erinacine A-enriched Hericium erinaceus mycelia as a preventive intervention in early-stage Alzheimer's disease patients. Over 49 weeks, the treatment group showed significantly better performance on cognitive assessments including the CASI and MMSE compared to placebo, along with reductions in biomarkers associated with amyloid-β plaque formation and tau protein deposition. The paper provides the most direct human clinical evidence to date that erinacines can cross the blood-brain barrier and modify neurodegenerative disease trajectories, lending clinical credibility to decades of preclinical mechanistic research.

Lowe, H., Toyang, N., Steele, B., Valentine, H., Grant, J., Ali, A., Ngwa, W., & Gordon, L. (2021). The therapeutic potential of psilocybin. Molecules, 26(10), 2948.

This open-access review surveys the accumulated evidence for psilocybin as a therapeutic agent across a range of psychiatric and neurological conditions, covering its mechanism of action as a serotonin 5-HT2A receptor agonist, its pharmacokinetic profile from ingestion through metabolic elimination, and clinical trial findings from studies targeting depression, anxiety, PTSD, addiction, and end-of-life psychological distress. The authors also discuss the regulatory and scheduling constraints that have historically slowed clinical research and outline pathways for expanded compassionate access. Published in Molecules under open access, the review provides a concise yet comprehensive entry point for researchers and clinicians approaching psilocybin's therapeutic applications for the first time.

Lu, H., Yang, Y., Gad, E., Inatsuka, C., Wenner, C. A., Disis, M. L., & Standish, L. J. (2011). Polysaccharide Krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells. Clinical Cancer Research, 17(1), 67–76.

This mechanistic study established that polysaccharide K (PSK, Krestin)—the commercially approved immunotherapy derived from Turkey Tail—activates innate immune responses through the Toll-like receptor 2 (TLR2) signaling pathway, providing the first definitive molecular mechanism for PSK's well-documented immunostimulatory effects. In both mouse tumor models and in vitro assays, PSK treatment significantly inhibited tumor growth and metastasis through CD8+ cytotoxic T cell and NK cell activation downstream of TLR2 signaling. Published in Clinical Cancer Research, this paper resolved a decades-long mechanistic question about how PSK works and provided the molecular rationale for its established clinical use as a cancer immunotherapy adjunct in Japan and China.

Łysakowska, P., Sobota, A., & Wirkijowska, A. (2023). Medicinal mushrooms: Their bioactive components, nutritional value and application in functional food production—A review. Molecules, 28(14), 5393.

This review systematically covers the bioactive components of major medicinal mushroom species—polysaccharides (β-glucans, heteroglycans), terpenoids (triterpenoids, diterpenes), sterols (ergosterol), phenolic compounds, and proteins (lectins, ribosome-inactivating proteins)—and their functional roles in immune modulation, antioxidant activity, and anti-inflammatory response. The authors evaluate how different processing methods such as drying, extraction solvent, and fermentation affect the stability and bioactivity of these compounds, with direct implications for functional food and nutraceutical manufacturing. The review serves as a thorough reference for anyone entering the field of medicinal mushroom food science.

Ma, B. J., Shen, J. W., Yu, H. Y., Ruan, Y., Wu, T. T., & Zhao, X. (2010). Hericenones and erinacines: Stimulators of nerve growth factor (NGF) biosynthesis in Hericium erinaceus. Mycology, 1(2), 92–98.

This review systematically catalogues hericenones (from the fruiting body) and erinacines (from the mycelium) as the two primary classes of bioactive compounds uniquely produced by Hericium erinaceus that stimulate nerve growth factor (NGF) biosynthesis. The authors detail the structural characteristics that distinguish each compound class, their respective potencies in in vitro NGF assays, and the evidence that erinacines—particularly erinacine A—are small enough to cross the blood-brain barrier, making mycelium-derived preparations potentially more relevant for neurodegenerative disease applications than fruiting body extracts. This paper remains the essential structural and mechanistic reference for anyone studying Lion's Mane's neuroprotective properties.

Mahadevan, K., Daoust, J., Brendler, T., Chaudhary, A., Saifi, A., & Garg, V. K. (2025). A toxicological assessment of Hericium erinaceus (Lion's mane) and Trametes versicolor (Turkey tail) mushroom powders. Frontiers in Toxicology, 7, 1651442.

Martinez-Burgos, W. J., Montes, E., Pozzan, R., Serra, J. L., Torres, D. O., Manzoki, M. C., Vieira, R. L., dos Reis, G. A., Rodrigues, C., & Karp, S. G. (2024). Bioactive compounds produced by macromycetes for application in the pharmaceutical sector: Patents and products. Fermentation, 10(6), 275. https://doi.org/10.3390/fermentation10060275

This review maps the commercialization of macromycete-derived bioactive compounds through analysis of patent databases and existing pharmaceutical products, providing a unique window into the industrial and regulatory landscape surrounding mushroom pharmaceuticals. The authors identify β-glucan-based immunomodulators (e.g., lentinan, schizophyllan) as the most commercially developed category, alongside emerging interest in ergothioneine as an antioxidant pharmaceutical ingredient and cordycepin as an antiviral candidate. The paper bridges academic research and commercial application, offering insight into which compounds are closest to widespread pharmaceutical use.

Matsuzaki, H., Shimizu, Y., Iwata, N., Kamiuchi, S., Suzuki, F., Iizuka, H., Hibino, Y., & Okazaki, M. (2013). Antidepressant-like effects of a water-soluble extract from the culture medium of Ganoderma lucidum mycelia in rats. BMC Complementary and Alternative Medicine, 13, 370.

This preclinical study administered a water-soluble extract from Ganoderma lucidum mycelium culture medium to rats, then assessed antidepressant-like behavior using established models including the forced swim test and tail suspension test. Rats treated with the extract showed dose-dependent reductions in immobility time comparable to conventional antidepressant controls, with measurements of monoamine levels (dopamine, serotonin, norepinephrine) suggesting increased neurotransmitter availability as a mechanism. The study provides a biological plausibility foundation for the antidepressant effects reported in human studies of Reishi, and is notably one of very few papers to investigate Ganoderma's potential in mood disorder research.

McGowan, N. M., Rucker, J. J., Yehuda, R., Agrawal, M., Modlin, N. L., Simmons, H., Tofil-Kaluza, A., Das, S., & Goodwin, G. M. (2025). Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial. Journal of Psychopharmacology, 40(1), 139–148.

This early trial tested whether a single dose of psilocybin is safe for people with PTSD (post-traumatic stress disorder). It was an open-label study. That means everyone knew they were getting psilocybin, and there was no comparison group. The treatment was generally safe, and patients showed signs of improvement. The authors stress that larger, controlled trials are still needed. It is free to read in the Journal of Psychopharmacology.

Menon, A., Jalal, A., Arshad, Z., Nawaz, F. A., & Kashyap, R. (2025). Benefits, side effects, and uses of Hericium erinaceus as a supplement: A systematic review. Frontiers in Nutrition, 12, 1641246.

Michalska, A., Szymanowska, U., Kapusta, I., Żurek, N., Nawrocka, A., Różyło, R., Jarocki, P., & Świeca, M. (2025). Antioxidant, anti-inflammatory, and antiproliferative properties of extracted Turkey tail (Trametes versicolor Lloyd) mushroom components microencapsulated with inulin. Food Chemistry, 495, 146348.

This experimental study developed and characterized inulin-based microencapsulated formulations of two bioactive fractions extracted from Turkey tail mushroom—a polysaccharide-rich aqueous fraction and an ethanol-extractable phenolic fraction—achieving encapsulation efficiencies exceeding 75% with preservation of antioxidant, anti-inflammatory, and antiproliferative activities in cancer cell line assays. The microencapsulation process protected bioactive compounds from degradation during food processing and simulated gastrointestinal digestion, enhancing their potential as functional food ingredients. The findings represent a meaningful step toward the practical application of turkey tail mushroom bioactives in commercial food products.

Money, N. P. (2016). Are mushrooms medicinal? Fungal Biology, 120(4), 449–453. https://doi.org/10.1016/j.funbio.2016.01.006

Written by a mycologist, this critical commentary evaluates the scientific evidence base for medicinal mushroom health claims with unusual rigor, concluding that while traditional Chinese medicine accounts are culturally significant, controlled clinical evidence for whole mushroom consumption producing measurable health benefits remains limited. The author acknowledges that certain purified compounds—particularly lentinan from shiitake and the NGF-stimulating erinacines and hericenones from Lion's Mane—show genuine pharmacological promise warranting further investigation. The piece serves as a useful corrective to uncritical enthusiasm and sets a clear standard for what constitutes adequate evidence in mushroom science.

Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006). Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. The Journal of Clinical Psychiatry, 67(11), 1735–1740.

This early study tested whether psilocybin is safe for people with obsessive-compulsive disorder, or OCD. Nine patients with hard-to-treat OCD took different doses of psilocybin in a controlled setting. The treatment was well tolerated, and many patients had a clear, if temporary, drop in their OCD symptoms. The authors say the results are promising enough to justify larger studies. This was only a small early trial. The abstract is free to read; the full article needs journal access.

Mori, K., Inatomi, S., Ouchi, K., Azumi, Y., & Tuchida, T. (2008). Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: A double-blind placebo-controlled clinical trial. Phytotherapy Research, 23(3), 367–372. https://doi.org/10.1002/ptr.2634

This landmark double-blind, placebo-controlled clinical trial enrolled 30 adults with mild cognitive impairment and administered 3 g of Hericium erinaceus powder daily for 16 weeks, finding significant improvements on the Hasegawa Dementia Scale compared to placebo, with effects declining after supplementation ended. The trial is considered the foundational human evidence linking Lion's Mane consumption directly to measurable cognitive benefit, and was among the first to demonstrate reversible dose-response dynamics in a clinical setting. Its findings have been replicated and extended in subsequent trials and continue to anchor mechanistic hypotheses around NGF-stimulated neurogenesis.

Morton, E., Sakai, K., Ashtari, A., Pleet, M., Michalak, E. E., & Woolley, J. (2022). Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of 'magic mushroom' consumption. Journal of Psychopharmacology, 37(1), 49–60.

This international online survey recruited 541 individuals with bipolar disorder who had personal experience using psilocybin mushrooms, gathering data on outcomes including mood episode induction, mental health effects, and adverse safety events. The majority of respondents reported predominantly beneficial effects including mood stabilization and reduced depressive symptoms; however, a meaningful minority reported adverse effects including manic or hypomanic episodes, indicating that bipolar disorder warrants particular caution in psilocybin research. The survey provides the largest dataset on psilocybin use in bipolar disorder to date and highlights the urgency of dedicated clinical trial research in this population.

Nagano, M., Shimizu, K., Kondo, R., Hayashi, C., Sato, D., Kitagawa, K., & Ohnuki, K. (2010). Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake. Biomedical Research, 31(4), 231–237.

This study investigated the effect of four weeks of Hericium erinaceus supplementation in 30 women with a range of health complaints, measuring changes on validated scales for depression, anxiety, concentration, and irritation. Women consuming lion's mane showed significantly lower scores on depression and anxiety compared to the placebo group, suggesting that the mushroom may influence mood through pathways beyond direct NGF stimulation—possibly including serotonin precursor activity (tryptophan) and anti-inflammatory effects. The study is notable for demonstrating mood benefits in non-clinical, community-dwelling women rather than diagnosed psychiatric patients.

Nicholas, C. R., Henriquez, K. M., Gassman, M. C., Cooper, K. M., Muller, D., Hetzel, S., Brown, R. T., Cozzi, N. V., Thomas, C., & Hutson, P. R. (2018). High dose psilocybin is associated with positive subjective effects in healthy volunteers. Journal of Psychopharmacology, 32(7), 770–778.

This dose-escalation study in healthy volunteers administered 5 mg, 10 mg, 20 mg, and 30 mg of psilocybin across multiple sessions, establishing that higher doses produced more intense and complete mystical experiences while remaining physiologically safe—no clinically significant cardiovascular events or other serious adverse events occurred across any dose level. Positive subjective effects (feelings of profound awe, unity, and insight) increased monotonically with dose, with 30 mg producing the most robust responses. The study provided critical safety and pharmacodynamic data that directly informed dose selection in subsequent clinical trials.

Niego, A. G., Rapior, S., Thongklang, N., Raspé, O., Jaidee, W., Lumyong, S., & Hyde, K. D. (2021). Macrofungi as a nutraceutical source: Promising bioactive compounds and market value. Journal of Fungi, 7(5), 397. https://doi.org/10.3390/jof7050397

This comprehensive review catalogues bioactive compounds from macrofungi (higher basidiomycetes) across multiple chemical classes—polysaccharides, terpenoids, sterols, phenolic compounds, lectins, and nucleosides—and evaluates their demonstrated and potential nutraceutical applications for immune health, metabolic disorders, and neuroprotection. The authors also analyze the global commercial market for macrofungi-derived nutraceuticals, estimating it at over USD 30 billion and growing rapidly. The review provides both scientific and commercial context for understanding why functional mushroom research has accelerated dramatically in recent years.

Nishizawa, K., Torii, K., Kawasaki, A., Katada, M., Ito, M., Nishimura, T., Kobayashi, M., Nemeroff, C. B., & Bhattacharya, S. K. (2007). Antidepressant-like effect of Cordyceps sinensis in the mouse tail suspension test. Biological and Pharmaceutical Bulletin, 30(9), 1758–1762.

This preclinical study administered Cordyceps sinensis extract to mice and evaluated behavior in the tail suspension test and forced swim test—two validated models of antidepressant action—finding significant reductions in immobility time consistent with antidepressant-like activity. Biochemical analysis revealed elevated levels of serotonin and norepinephrine in the frontal cortex of treated animals, suggesting that Cordyceps modulates monoamine neurotransmission in regions implicated in mood regulation. The study is the primary preclinical reference for Cordyceps's antidepressant potential and provides mechanistic support for its traditional use as a mood-regulating adaptogen.

Passie, T., Seifert, J., Schneider, U., & Emrich, H. M. (2002). The pharmacology of psilocybin. Addiction Biology, 7(4), 357–364.

This foundational pharmacological review synthesizes research on psilocybin's absorption, distribution, metabolism, and excretion—documenting its rapid conversion to the active metabolite psilocin via alkaline phosphatases after ingestion, with peak plasma concentrations occurring within approximately 90 minutes and near-complete elimination within 8–10 hours. The review covers dose-response relationships, tolerance effects, interactions with other serotonergic compounds, and the relative receptor binding profile of psilocin at serotonin receptor subtypes. As one of the first comprehensive reviews of psilocybin pharmacology in English, this remains an essential reference for understanding psilocybin's mechanism of action.

Pazzi, F., Adsuar, J. C., Domínguez-Muñoz, F. J., García-Gordillo, M. A., Gusi, N., & Collado-Mateo, D. (2020). Ganoderma lucidum effects on mood and health-related quality of life in women with fibromyalgia. Healthcare, 8(4), 520.

This Italian clinical study enrolled women with fibromyalgia—a chronic pain condition with strong comorbid psychological components—and evaluated the effects of 6 weeks of Ganoderma lucidum supplementation on mood, quality of life, fatigue, and pain perception using validated scales. The Reishi group showed significant improvements in depressive symptoms, fatigue, and global quality-of-life scores compared to placebo, adding human clinical evidence for Reishi's impact on psychological well-being in a chronic illness context. The study is notable for targeting a patient population with documented neuroimmune dysregulation, making it particularly relevant to discussions of Reishi's adaptogenic and anti-inflammatory mechanisms.

Sainikhitha, A., & Fathima, S. N. (2025). Medicinal mushrooms: Pharmacological perspectives and therapeutic potential. Journal of Advance and Future Research, 3(11), JAAFR2511348.

This pharmacology-focused review examines the mechanistic basis for therapeutic claims surrounding major medicinal mushroom species including Reishi, Lion's Mane, Shiitake, Turkey Tail, Chaga, and Cordyceps, providing species-by-species breakdowns of key bioactive compounds, receptor and signaling pathway interactions, and documented clinical and preclinical evidence. The authors highlight Hericium erinaceus's dual mechanism of NGF stimulation and reduction of amyloid-β accumulation as particularly promising for neurodegenerative disease applications. The review effectively bridges traditional ethnopharmacological knowledge with contemporary molecular pharmacology.

Saleh, M. H., Rashedi, I., & Keating, A. (2017). Immunomodulatory properties of Coriolus versicolor: The role of polysaccharopeptide. Frontiers in Immunology, 8, 1087.

This comprehensive review examines the immunomodulatory properties of polysaccharopeptide (PSP)—the second major bioactive fraction of Coriolus versicolor (Turkey Tail)—distinguishing it from the better-studied PSK (Krestin) and synthesizing evidence for its effects on macrophage activation, cytokine signaling, T cell polarization, and NK cell function. The authors conclude that PSP operates through multiple overlapping immune pathways involving TLR2/TLR4 activation and modulation of M1/M2 macrophage phenotype balance, and identify it as a promising candidate for combination immunotherapy in cancer treatment. The review provides the most thorough mechanistic treatment of PSP available in the immunology literature.

Sathvara, A. B., & Afuwale, C. D. (2024). A comprehensive review on mushrooms as a nutraceutical superfood. International Journal of Contemporary Microbiology, 12(2), 22–33.

This review examines mushrooms as nutraceutical superfoods, surveying their key bioactive components—β-glucans, ergothioneine, antioxidants, and bioactive polysaccharides—alongside their multiple health benefits including immune modulation, anti-inflammatory activity, blood glucose regulation, and cholesterol management. The authors also examine how different processing methods such as hot-water extraction, freeze-drying, and spray-drying affect mushroom bioactivity, with implications for supplement and food product formulation. The review offers a practical guide to the nutritional and health-promoting properties that have driven rapid growth in the functional mushroom supplement market.

Shao, L. X., Liao, C., Bhatt, D. L., & Bhatt, D. (2021). Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron, 109(16), 2535–2544.

Using in vivo two-photon microscopy in mice, this study demonstrated that a single dose of psilocybin produced rapid (within 24 hours) and persistent (at least one month) growth of new dendritic spines in the frontal cortex, reversing the spine loss associated with chronic stress exposure. Mice subjected to chronic stress and treated with psilocybin showed normalized behavior on multiple behavioral assays compared to untreated stress-exposed controls. This study provided the first direct structural evidence of psilocybin's neuroplasticity effects at the synaptic level and proposed a compelling mechanism for the durable antidepressant effects observed in clinical studies.

Spriggs, M. J., Douglass, H. M., Park, R. J., Read, T., Danby, J. L., de Magalhães, F. J. C., Alderton, K. L., Williams, T. M., Blemings, A., Lafrance, A., Nicholls, D. E., Erritzoe, D., Nutt, D. J., & Carhart-Harris, R. L. (2021). Study protocol for "Psilocybin as a treatment for anorexia nervosa: A pilot study". Frontiers in Psychiatry, 12, Article 735523.

This paper is a study protocol, which means it lays out the plan for a clinical trial before it is run. The trial will test whether psilocybin therapy can help people with anorexia nervosa, a serious eating disorder. The authors explain how they will measure safety, the patient experience, and changes in eating-related thoughts. Because it is a plan rather than results, it does not yet show whether the treatment works. It is free to read in Frontiers in Psychiatry.

Sreedharan, P. L., Kishorkumar, M., Neumann, E. G., & Kurup, S. S. (2025). The emerging role of oyster mushrooms as a functional food for complementary cancer therapy. Foods, 14(1), 128.

Tang, W., Gao, Y., Chen, G., Gao, H., Dai, X., Ye, J., Chan, E., Huang, M., & Zhou, S. (2005). A randomized, double-blind and placebo-controlled study of a Ganoderma lucidum polysaccharide extract in neurasthenia. Journal of Medicinal Food, 8(1), 53–58.

This randomized, double-blind, placebo-controlled trial enrolled 132 patients with neurasthenia—a condition characterized by persistent fatigue, weakness, and anxiety—and administered a standardized Ganoderma lucidum polysaccharide extract for 8 weeks. Patients in the Reishi group showed significant improvements in fatigue scores, well-being ratings, and quality-of-life measures compared to placebo, with a favorable safety profile. Published in the Journal of Medicinal Food, this trial is frequently cited as the strongest human clinical evidence for Reishi's adaptogenic and fatigue-relieving properties, representing one of the few placebo-controlled trials of Reishi in a defined clinical population.

Tianzhu, Z., Shihai, Y., & Juan, D. (2014). Antidepressant-like effects of cordycepin in a mice model of chronic unpredictable mild stress. Evidence-Based Complementary and Alternative Medicine, 2014, 438506.

This study assessed cordycepin—the primary bioactive nucleoside of Cordyceps militaris—as an antidepressant agent using the chronic unpredictable mild stress (CUMS) mouse model, which produces reliable depression-like phenotypes including anhedonia, reduced social interaction, and decreased sucrose preference. Cordycepin treatment dose-dependently reversed all behavioral markers of depression and was associated with significantly elevated BDNF expression in the hippocampus, identifying brain-derived neurotrophic factor upregulation as a plausible molecular mechanism. The study builds on earlier Cordyceps antidepressant research by isolating cordycepin as the active compound responsible for mood effects, with implications for standardized formulation of Cordyceps-based mental health supplements.

Torkelson, C. J., Sweet, E., Martzen, M. R., Sasagawa, M., Wenner, C. A., Gay, J., Putiri, A., & Standish, L. J. (2012). Phase 1 clinical trial of Trametes versicolor in women with breast cancer. International Scholarly Research Notices Oncology, 2012, 251632.

This Phase 1 clinical trial administered escalating doses of Trametes versicolor (Turkey Tail) mushroom powder to 9 women who had completed conventional treatment for breast cancer, assessing safety, immune reconstitution, and dosing tolerability up to 9 g/day for 6 weeks. All doses were well tolerated, and dose-dependent increases in NK cell activity and CD8+ T cell counts were observed—critically important findings for a population whose immune function is often suppressed by chemotherapy and radiation. As the first prospective clinical trial of Turkey Tail in breast cancer patients, this paper opened the pathway for subsequent Phase 2 trials and remains the primary clinical safety reference for Turkey Tail supplementation.

Tuli, H. S., Sandhu, S. S., & Sharma, A. K. (2014). Pharmacological and therapeutic potential of Cordyceps with special reference to cordycepin. 3 Biotech, 4(1), 1–12.

Cordyceps is a fungus that has been used in traditional medicine for a long time. This review focuses on its main active ingredient, called cordycepin. In lab and animal studies, cordycepin has shown anti-cancer, antioxidant, and anti-inflammatory effects. Researchers have seen these effects in the immune system, liver, kidneys, and heart. The authors say cordycepin looks promising. But it is not ready for wide medical use yet. First, scientists need better ways to make it in large amounts. The article is free to read in the journal 3 Biotech.

Vigna, L., Morelli, F., Agnelli, G. M., Napolitano, F., Ratto, D., Occhinegro, A., Di Iorio, C., Savino, E., Girometta, C., Brandalise, F., & Rossi, P. (2019). Hericium erinaceus improves mood and sleep disorders in patients affected by overweight or obesity: Could circulating pro-BDNF and BDNF be potential biomarkers? Evidence-Based Complementary and Alternative Medicine, 2019, 7861297.

This Italian clinical study enrolled overweight and obese patients, administering Hericium erinaceus supplementation over 8 weeks and measuring circulating BDNF and pro-BDNF alongside validated scales for mood and sleep quality. Participants in the Lion's Mane group showed significant improvements in mood and sleep disorders, with accompanying changes in pro-BDNF/BDNF ratios suggesting a biologically plausible mechanism involving neurotrophic signaling. The study is the first to link Lion's Mane-associated mood benefits to measurable changes in circulating brain-derived neurotrophic factor in humans.

Vollenweider, F. X., & Preller, K. H. (2020). Psychedelic drugs: Neurobiology and potential for treatment of psychiatric disorders. Nature Reviews Neuroscience, 21(11), 611–624.

This review explains how psychedelic drugs like psilocybin and LSD work in the brain and why they may help treat mental illness. The authors describe how these drugs act on a serotonin receptor and change activity in brain networks tied to mood and self-focus. They connect these brain effects to improvements seen in depression, anxiety, and addiction. The review also points out what is still unknown and where research should go next. The abstract is free to read; the full article needs journal access.

Wachtel-Galor, S., Yuen, J., Buswell, J. A., & Benzie, I. F. F. (2011). Ganoderma lucidum (Lingzhi or Reishi): A medicinal mushroom. In Benzie, I. F. F., & Wachtel-Galor, S. (Eds.), Herbal Medicine: Biomolecular and Clinical Aspects (2nd ed.). CRC Press/Taylor & Francis.

This book chapter provides the most comprehensive scientific overview of Ganoderma lucidum (Reishi/Lingzhi) available in a peer-reviewed academic reference work, covering botany, cultivation, phytochemistry (polysaccharides, triterpenoids, sterols, alkaloids), immunopharmacology, anticancer mechanisms, clinical evidence, and safety and toxicity data in a single authoritative source. The authors synthesize evidence across preclinical and clinical research, identifying immunomodulation and quality-of-life support for cancer patients as the strongest evidence domains while honestly documenting rare hepatotoxicity cases from concentrated powdered preparations. Published in a CRC Press medical reference widely cited in both academic papers and clinical guidelines, this chapter serves as the foundational reference for Reishi's evidence-based pharmacology.

Yu, F., Tafur, J., Moreno, F., & Dahmer, S. (2026). Inaugural year of regulated psilocybin services in Oregon: Safety, motivations, and utilization. Frontiers in Psychiatry, 17, 1777387.

Zhang, Y., Zhang, M., Jiang, Y., Li, X., He, Y., Zeng, P., Guo, Z., Chang, Y., Luo, H., & Liu, Y. (2018). Lentinan as an immunotherapeutic for treating lung cancer: A review of 12 years clinical studies in China. Journal of Cancer Research and Clinical Oncology, 144(11), 2177–2186.

This review synthesizes 12 years of clinical study data on lentinan as an immunotherapeutic for lung cancer in China, identifying 18 clinical trials involving over 2,000 patients in whom lentinan combined with chemotherapy or radiotherapy produced consistently improved response rates, quality-of-life scores, and survival outcomes compared to conventional treatment alone. The authors attribute lentinan's benefits to its macrophage-activating and T cell-potentiating properties, which partially compensate for the immunosuppression induced by cytotoxic cancer therapies. This paper is the most comprehensive clinical evidence synthesis for lentinan in thoracic oncology and is frequently cited as a key reference for the biological response modifier classification of Shiitake-derived compounds.

Zhang, M., Zhang, Y., Zhang, L., & Tian, Q. (2019). Mushroom polysaccharide lentinan for treating different types of cancers: A review of 12 years clinical studies in China. Progress in Molecular Biology and Translational Science, 163, 297–328.

This book chapter review expands the lentinan clinical evidence synthesis beyond gastric cancer to cover multiple cancer types including colorectal, cervical, liver, and breast cancers, compiling data from Chinese and Japanese clinical trials conducted over 12 years and summarizing response rates, survival benefits, and quality-of-life improvements across patient populations. The authors discuss the biological basis for lentinan's broad-spectrum immunotherapy effects—including NK cell activation, macrophage reprogramming, and T-helper cell polarization—and address formulation considerations including intravenous versus oral delivery routes. The comprehensive coverage of lentinan across multiple oncological settings makes this chapter the most authoritative single reference for lentinan's clinical scope.